Charles River Laboratories International, Inc. (CRL): Price and Financial Metrics


Charles River Laboratories International, Inc. (CRL): $418.39

7.15 (+1.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CRL POWR Grades


  • CRL scores best on the Sentiment dimension, with a Sentiment rank ahead of 89.99% of US stocks.
  • CRL's strongest trending metric is Quality; it's been moving down over the last 31 weeks.
  • CRL's current lowest rank is in the Momentum metric (where it is better than 42.79% of US stocks).

CRL Stock Summary

  • CRL has a higher market value than 88.07% of US stocks; more precisely, its current market capitalization is $20,082,029,531.
  • CRL's current price/earnings ratio is 53.54, which is higher than 82.11% of US stocks with positive earnings.
  • The price/operating cash flow metric for Charles River Laboratories International Inc is higher than 83.77% of stocks in our set with a positive cash flow.
  • If you're looking for stocks that are quantitatively similar to Charles River Laboratories International Inc, a group of peers worth examining would be BR, QRVO, WDC, TRMB, and VRSK.
  • CRL's SEC filings can be seen here. And to visit Charles River Laboratories International Inc's official web site, go to www.criver.com.

CRL Valuation Summary

  • In comparison to the median Healthcare stock, CRL's EV/EBIT ratio is 47.19% higher, now standing at 39.3.
  • CRL's EV/EBIT ratio has moved up 5.9 over the prior 243 months.
  • Over the past 243 months, CRL's price/earnings ratio has gone up 295.9.

Below are key valuation metrics over time for CRL.

Stock Date P/S P/B P/E EV/EBIT
CRL 2021-07-13 6.3 8.8 51.3 38.1
CRL 2018-08-07 3.2 5.4 47.6 22.7
CRL 2014-06-10 2.3 3.8 24.2 19.7
CRL 2011-07-08 1.9 3.8 -6.7 -9.7
CRL 2001-12-19 3.2 5.0 45.1 19.1
CRL 2001-11-02 3.7 6.8 -364.8 34.9

CRL Growth Metrics

  • The 2 year net income to common stockholders growth rate now stands at 91.67%.
  • The 3 year price growth rate now stands at 69.93%.
  • Its year over year price growth rate is now at 116.5%.
Over the past 34 months, CRL's revenue has gone up $1,019,460,000.

The table below shows CRL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 3,041.44 648.214 375.065
2020-12-31 2,923.933 546.575 364.304
2020-09-30 2,824.081 588.873 301.461
2020-06-30 2,748.732 567.42 271.362
2020-03-31 2,723.716 534.667 247.655
2019-12-31 2,621.226 480.936 252.019

CRL Price Target

For more insight on analysts targets of CRL, see our CRL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $375.25 Average Broker Recommendation 1.4 (Strong Buy)

CRL Stock Price Chart Interactive Chart >

Price chart for CRL

CRL Price/Volume Stats

Current price $418.39 52-week high $420.25
Prev. close $411.24 52-week low $197.33
Day low $406.09 Volume 350,180
Day high $420.25 Avg. volume 444,846
50-day MA $369.17 Dividend yield N/A
200-day MA $298.67 Market Cap 21.03B

Charles River Laboratories International, Inc. (CRL) Company Bio


Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.

CRL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$418.39$133.63 -59%

We started the process of determining a valid price forecast for Charles River Laboratories International Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Charles River Laboratories International Inc ranked in the 31th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 59%. In terms of the factors that were most noteworthy in this DCF analysis for CRL, they are:

  • 88% of the company's capital comes from equity, which is greater than 64.66% of stocks in our cash flow based forecasting set.
  • As a business, Charles River Laboratories International Inc experienced a tax rate of about 13% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 55.55% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-60%
1%-60%
2%-59%
3%-59%
4%-58%
5%-58%

DHR, GMED, HAPP, NRC, and NVS can be thought of as valuation peers to CRL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


CRL Latest News Stream


Event/Time News Detail
Loading, please wait...

CRL Latest Social Stream


Loading social stream, please wait...

View Full CRL Social Stream

Latest CRL News From Around the Web

Below are the latest news stories about Charles River Laboratories International Inc that investors may wish to consider to help them evaluate CRL as an investment opportunity.

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

Yahoo | July 29, 2021

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 28, 2021

Biomonitoring and Bioburden Testing Market Size, Key Opportunities, Strategic Assessment, Strong Revenue | Oprating Vendors: Merck, STERIS Laboratories, Charles River Laboratories International, Lu

The documented report on Global Biomonitoring and Bioburden Testing Market by Reports Globe aims to offer an organized and methodical strategy for important aspects that have affected the market in recent years and future market opportunities that companies can trust. It gives readers clear market research for better judgment and better decision making on whether []

Jumbo News | July 25, 2021

Global Automated Microbial Identification Systems Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Charles River Laboratories International, Inc. (US), Nelson Laboratories (US), WuXi PharmaTech (Cayman) Inc. (China), Sigma-Aldrich Corporation (US), North American Science Associates, Inc. (NAMSA) (US), SGS S.A. (Switzerland), ATS Labs, Inc. (US), Becton, Dickinson

The report on Global Automated Microbial Identification Systems Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []

Jumbo News | July 23, 2021

Global Human Microbiome Sequencing Instrument Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Baseclear B.V., Novogene Corporation, Clinical Microbiomics A/S, Beijing Genomics Institute (BGI) Genomics Co., Ltd, Illumina, Inc., Charles River Laboratories International Inc., Oxford Nanopore Technologies, Inc., GENEWIZ, Inc., Eurofins Scientific SE, OraSure Technolo

The report on Global Human Microbiome Sequencing Instrument Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []

Jumbo News | July 23, 2021

Read More 'CRL' Stories Here

CRL Price Returns

1-mo N/A
3-mo 24.21%
6-mo 51.72%
1-year 105.17%
3-year 227.56%
5-year 388.09%
YTD 67.45%
2020 63.56%
2019 34.97%
2018 3.41%
2017 43.65%
2016 -5.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8034 seconds.